secwatch.observer — SEC 8-K summary
======================================

Issuer:     MUSTANG BIO, INC. (MBIO)
CIK:        0001680048
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001558370-23-012508
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mustang Bio closes amended asset sale to uBriGene for $6M upfront; cash runway into early 2024
--------------------------------------------------------------------------------

- Closed amended asset purchase agreement with uBriGene on July 28, 2023; received $6M upfront cash.
- Additional $5M contingent payment requires Mustang to raise $10M+ equity and landlord consent for lease assignment.
- Facility lease did not transfer; Mustang continues to occupy and manufacture MB-106; landlord has 30 days after CFIUS review.
- If lease not transferred within 120 days, uBriGene can request repurchase negotiations of transferred assets.
- Upfront proceeds and operating expense reductions extend cash runway into early 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023012508/0001558370-23-012508-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680048/000155837023012508/tmb-20230728x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-012508

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer